Skip to content
HomeLatest newsA message from Chairman and CEO Alex Gorsky about Johnson & Johnson’s investigational COVID-19 vaccine candidate
lede-A Message from Chairman and CEO Alex Gorsky About Johnson & Johnson's Investigational COVID-19 Vaccine Candidate.jpg

A message from Chairman and CEO Alex Gorsky about Johnson & Johnson’s investigational COVID-19 vaccine candidate

The company leader shares the latest news about topline results from the Phase 3 clinical trial for its single-dose investigational COVID-19 vaccine candidate.

One year ago this week, Johnson & Johnson pledged that we would leverage all of our capabilities to fight an emerging threat, then being referred to as simply “the novel coronavirus.” Since then, we have focused our efforts on delivering a single-dose vaccine that would be a safe, effective and efficient solution for the largest number of people around the world.

I couldn’t be more proud—or grateful—to share that we have made a significant step towards reaching our ambitious goal.

Today, we shared positive topline Phase 3 clinical trial results for our single-dose investigational COVID-19 vaccine candidate. We will continue to work with health authorities around the world on regulatory applications.

Johnson & Johnson was built for times like these—and from day one, we have kept science, transparency and collaboration at the center of all our efforts to fight this deadly pandemic.

COVID-19 has touched the lives of every person on this planet and tested us as a society and as individuals. But Johnson & Johnson was built for times like these—and from day one, we have kept science, transparency and collaboration at the center of all our efforts to fight this deadly pandemic. Our work on an investigational COVID-19 vaccine will be an enduring point of pride for us for decades to come.

Doing our part to combat the greatest public health crisis in living memory has been a huge undertaking for our company. I owe a deep debt of gratitude to the incredible teams that made this milestone a reality, and to each and every one of my 135,000 colleagues for living into Our Credo values with great resilience and agility to ensure we keep meeting the healthcare needs of all who rely on Johnson & Johnson.

COVID-19 continues to inflict heartbreak and hardship, and there is still much that must be done to bring this pandemic to an end. But I am more optimistic than ever that these dark days are numbered.

I hope that our announcement today serves as a welcome reminder of the transformative power of science, the multiplying effect of collaboration and—most of all—the possibility of a better, healthier future.

Stay Up to Date on Johnson & Johnson’s Janssen COVID-19 Vaccine

See answers to frequently asked questions, learn about the company’s innovative vaccine technology platform and more.
A close-up view of the novel coronavirus

More from Johnson & Johnson

Meet the medical engineer behind the innovative heart pump that revolutionized cardiac health

Drawing on his fascination with airplane technology, Thorsten Siess, Ph.D., came up with an idea that became the Impella heart pump. Now, 25 years since it entered the market, this groundbreaking device has helped more than 330,000 patients recover from heart injuries.

What you need to know about Johnson & Johnson’s 2024 third quarter earnings

Check out this infographic breakdown of the company’s third quarter performance, with highlights from its Innovative Medicine and MedTech businesses.

What is a rheumatic disease?

More than 200 conditions are classified as rheumatic diseases, including rheumatoid arthritis, lupus and Sjögren’s disease. They tend to affect the joints and connective tissues, causing pain and swelling and impacting quality of life. Here’s what a doctor wants you to know about the different types, symptoms and risk factors—and how Johnson & Johnson is innovating new treatments.